Predictive modeling of in vivo response to gemcitabine in pancreatic cancer

A clear contradiction exists between cytotoxic in-vitro studies demonstrating effectiveness of Gemcitabine to curtail pancreatic cancer and in-vivo studies failing to show Gemcitabine as an effective treatment. The outcome of chemotherapy in metastatic stages, where surgery is no longer viable, show...

Full description

Saved in:
Bibliographic Details
Published in:PLoS computational biology 2013-09, Vol.9 (9), p.e1003231
Main Authors: Lee, James J, Huang, Justin, England, Christopher G, McNally, Lacey R, Frieboes, Hermann B
Format: Article
Language:English
Subjects:
Animals
Antimetabolites, Antineoplastic - therapeutic use
Apoptosis
Cell growth
Chemotherapy
Cytotoxicity
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Dosage and administration
Drug interactions
Drug therapy
Experiments
Female
Gemcitabine
Histology
Humans
Mathematical models
Mice
Mice, SCID
Pancreas
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - pathology
Studies
Substance abuse treatment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A clear contradiction exists between cytotoxic in-vitro studies demonstrating effectiveness of Gemcitabine to curtail pancreatic cancer and in-vivo studies failing to show Gemcitabine as an effective treatment. The outcome of chemotherapy in metastatic stages, where surgery is no longer viable, shows a 5-year survival
ISSN:1553-7358
1553-734X
1553-7358
DOI:10.1371/journal.pcbi.1003231